UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The prognostic value of lymph node staging with prostate‐specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) and extended pelvic lymph node dissection in node‐positive patients with prostate cancer

BJU international, 2023-03, Vol.131 (3), p.330-338

2023

Volltextzugriff (PDF)

Predicting early outcomes in patients with intermediate‐ and high‐risk prostate cancer using prostate‐specific membrane antigen positron emission tomography and magnetic resonance imaging

BJU international, 2022-01, Vol.129 (1), p.54-62

2022

Volltextzugriff (PDF)

Standardised uptake values as determined on prostate‐specific membrane antigen positron emission tomography/computed tomography is associated with oncological outcomes in patients with prostate cancer

BJU international, 2022-06, Vol.129 (6), p.768-776

2022

Volltextzugriff (PDF)

Using prostate‐specific membrane antigen positron‐emission tomography to guide prostate biopsies and stage men at high‐risk of prostate cancer

BJU international, 2023-12, Vol.132 (6), p.705-712

2023

Volltextzugriff (PDF)

The oncological characteristics of non‐prostate‐specific membrane antigen (PSMA)‐expressing primary prostate cancer on preoperative PSMA positron emission tomography/computed tomography

BJU international, 2022-12, Vol.130 (6), p.750-753

2022

Volltextzugriff (PDF)

The clinical characteristics of patients with primary non‐prostate‐specific membrane antigen‐expressing prostate cancer on preoperative positron emission tomography/computed tomography

BJU international, 2022-03, Vol.129 (3), p.314-317

2022

Volltextzugriff (PDF)

E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET

European journal of nuclear medicine and molecular imaging, 2021-05, Vol.48 (5), p.1626-1638

2021

Volltextzugriff (PDF)

M1a prostate cancer: Results of a Dutch multidisciplinary consensus meeting

BJUI compass, 2021-05, Vol.2 (3), p.159-168

2021

Volltextzugriff (PDF)

Optimization and validation of 18F-DCFPyL PET radiomics-based machine learning models in intermediate- to high-risk primary prostate cancer

PloS one, 2023-11, Vol.18 (11), p.e0293672-e0293672

2023

Volltextzugriff (PDF)

Targeting PSMA Revolutionizes the Role of Nuclear Medicine in Diagnosis and Treatment of Prostate Cancer

Cancers, 2022-02, Vol.14 (5), p.1169

2022

Volltextzugriff (PDF)

How to attract young talent to nuclear medicine step 1: a survey conducted by the EANM Oncology and Theranostics Committee to understand the expectations of the next generation

European journal of nuclear medicine and molecular imaging, 2023-12, Vol.51 (1), p.3-11

2023

Volltextzugriff (PDF)

Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3-4N0-1 non-small cell lung cancer: the INCREASE trial

BMC cancer, 2020-08, Vol.20 (1), p.764-10, Article 764

2020

Volltextzugriff (PDF)

Quantitative implications of the updated EARL 2019 PET–CT performance standards

EJNMMI physics, 2019-12, Vol.6 (1), p.28-16, Article 28

2019

Volltextzugriff (PDF)

Bone Metastases Are Measurable: The Role of Whole-Body MRI and Positron Emission Tomography

Frontiers in oncology, 2021-11, Vol.11, p.772530-772530

2021

Volltextzugriff (PDF)

Molecular Targeted Positron Emission Tomography Imaging and Radionuclide Therapy of Pancreatic Ductal Adenocarcinoma

Cancers, 2021-12, Vol.13 (24), p.6164

2021

Volltextzugriff (PDF)

Pharmacological Optimization of PSMA-Based Radioligand Therapy

Biomedicines, 2022-11, Vol.10 (12), p.3020

2022

Volltextzugriff (PDF)

Head-To-Head Comparison of PET and Perfusion Weighted MRI Techniques to Distinguish Treatment Related Abnormalities from Tumor Progression in Glioma

Cancers, 2023-05, Vol.15 (9), p.2631

2023

Volltextzugriff (PDF)

Response Prediction and Evaluation Using PET in Patients with Solid Tumors Treated with Immunotherapy

Cancers, 2021-06, Vol.13 (12), p.3083

2021

Volltextzugriff (PDF)

Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer

European journal of nuclear medicine and molecular imaging, 2021-02, Vol.48 (2), p.469-476

2021

Volltextzugriff (PDF)

HOW TO REPORT PSMA PET

Seminars in nuclear medicine, 2024-01, Vol.54 (1), p.14-29

2024

Volltextzugriff (PDF)

Lymph node classification in E‑PSMA reporting guidelines for PSMA‑PET

European journal of nuclear medicine and molecular imaging, 2022-12, Vol.50 (1), p.10-11

2022

Volltextzugriff (PDF)

Dual-phase PET-CT to differentiate [18F]Fluoromethylcholine uptake in reactive and malignant lymph nodes in patients with prostate cancer

PloS one, 2012-10, Vol.7 (10), p.e48430-e48430

2012

Volltextzugriff (PDF)

1 – 25 von 146

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(146)
Mit Volltextzugriff
(129)

Publikationsform

Artikel
(146)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(87)
Life Sciences & Biomedicine
(85)
Prostate Cancer
(67)
Humans
(52)
Oncology
(42)
Male
(38)
Tomography
(38)
Radiology, Nuclear Medicine & Medical Imaging
(32)
Metastasis
(31)
Positron Emission Tomography
(31)
Tumors
(31)
Computed Tomography
(30)
Urology & Nephrology
(30)
Patients
(29)
Antigens
(28)
Medicine
(28)
Metastases
(28)
Medicine & Public Health
(27)
Medical Imaging
(25)
Nuclear Medicine
(25)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

The prognostic value of lymph node staging with prostate‐specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) and extended pelvic lymph node dissection in node‐positive patients with prostate cancer

Predicting early outcomes in patients with intermediate‐ and high‐risk prostate cancer using prostate‐specific membrane antigen positron emission tomography and magnetic resonance imaging

Standardised uptake values as determined on prostate‐specific membrane antigen positron emission tomography/computed tomography is associated with oncological outcomes in patients with prostate cancer

Using prostate‐specific membrane antigen positron‐emission tomography to guide prostate biopsies and stage men at high‐risk of prostate cancer

The oncological characteristics of non‐prostate‐specific membrane antigen (PSMA)‐expressing primary prostate cancer on preoperative PSMA positron emission tomography/computed tomography

The clinical characteristics of patients with primary non‐prostate‐specific membrane antigen‐expressing prostate cancer on preoperative positron emission tomography/computed tomography

E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET

M1a prostate cancer: Results of a Dutch multidisciplinary consensus meeting

Optimization and validation of 18F-DCFPyL PET radiomics-based machine learning models in intermediate- to high-risk primary prostate cancer

Targeting PSMA Revolutionizes the Role of Nuclear Medicine in Diagnosis and Treatment of Prostate Cancer

How to attract young talent to nuclear medicine step 1: a survey conducted by the EANM Oncology and Theranostics Committee to understand the expectations of the next generation

Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3-4N0-1 non-small cell lung cancer: the INCREASE trial

Quantitative implications of the updated EARL 2019 PET–CT performance standards

Bone Metastases Are Measurable: The Role of Whole-Body MRI and Positron Emission Tomography

Molecular Targeted Positron Emission Tomography Imaging and Radionuclide Therapy of Pancreatic Ductal Adenocarcinoma

Irreversible Electroporation and Nivolumab Combined with Intratumoral Administration of a Toll-Like Receptor Ligand, as a Means of In Vivo Vaccination for Metastatic Pancreatic Ductal Adenocarcinoma (PANFIRE-III). A Phase-I Study Protocol

Pharmacological Optimization of PSMA-Based Radioligand Therapy

EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer—2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent

Head-To-Head Comparison of PET and Perfusion Weighted MRI Techniques to Distinguish Treatment Related Abnormalities from Tumor Progression in Glioma

Response Prediction and Evaluation Using PET in Patients with Solid Tumors Treated with Immunotherapy

EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II—2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer

Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer

HOW TO REPORT PSMA PET

Lymph node classification in E‑PSMA reporting guidelines for PSMA‑PET

Dual-phase PET-CT to differentiate [18F]Fluoromethylcholine uptake in reactive and malignant lymph nodes in patients with prostate cancer

Suchergebnisse filtern